Zydus Ahmedabad facility gets 4 USFDA observations
Ahmedabad: Zydus Lifesciences has recently announced that the US Food and Drug Administration (USFDA) has issued four observations after the inspection of the company's Moraiya manufacturing facility located at Ahmedabad.The inspection was conducted from 26th July to 5th August 2022."We wish to inform that the USFDA conducted an inspection of our Moraiya manufacturing facility located...
Ahmedabad: Zydus Lifesciences has recently announced that the US Food and Drug Administration (USFDA) has issued four observations after the inspection of the company's Moraiya manufacturing facility located at Ahmedabad.
The inspection was conducted from 26th July to 5th August 2022.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the manufacture of generic drugs. Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd